Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MESO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Rexlemestrocel-L | Degenerative Disc Disease | Phase 3 · NCT06325566 | Active not recruiting |
| Remestemcel-L-Rknd | GVHD - Graft-Versus-Host Disease | Phase 3 · NCT07568535 | Not yet recruiting |
| Remestemcel-L | Mesenchymal Stromal Cells | Phase 3 · NCT04371393 | Terminated |
| Infusion of one MPC expanded cord unit and one… | Acute Myelogenous Leukemia | Phase 3 · NCT01854567 | Completed |
| Infusion of two unexpanded cord blood units. | Acute Myelogenous Leukemia | Phase 3 · NCT01854567 | Completed |
| PROCHYMAL adult human mesenchymal stem cells | Crohn's Disease | Phase 3 · NCT00543374 | Completed |
| NeoFuse | Cervical Degenerative Disc Disease | Phase 1/2 · NCT01106417 | Completed |
| Stem Cell | Degenerative Disc Disease | Phase 1/2 · NCT00810212 | Withdrawn |
| Lumbar Interbody Fusion with Autograft | Degenerative Disc Disease | Phase 2 · NCT00996073 | Completed |
| Allogeneic Mesenchymal Precursor Cells | Rheumatoid Arthritis | Phase 2 · NCT01851070 | Completed |
| Autologous Expanded Mesenchymal Stem Cells… | Graft Versus Host Disease | Phase 2 · NCT00081055 | Withdrawn |
| Chondrogen | Recovery Following Partial Medial Meniscectomy | Phase 1/2 · NCT00702741 | Completed |
| Hyaluronic Acid | Recovery Following Partial Medial Meniscectomy | Phase 1/2 · NCT00225095 | Completed |
| Mesenchymal Precursor Cells (MPC) 12.5 M | Acute Myocardial Infarction | Phase 2 · NCT01781390 | Completed |
| Mesenchymal Precursor Cells (MPC) 25 M | Acute Myocardial Infarction | Phase 2 · NCT01781390 | Completed |
| Mesenchymal Precursor Cells (MPCs) | Type 2 Diabetes | Phase 1/2 · NCT01576328 | Completed |
Also used in these trials (approved or third-party drugs, not MESO's own candidates): Mycophenolate Mofetil, Prednisone, Tacrolimus Extended-Release, Busulfan, Cyclophosphamide, Cyclosporine, Methotrexate, Hydrocortisone, Diphenhydramine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MESO holds $102.9M in cash and short-term investments and burns about $11M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MESO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Silviu Itescu CEO and Managing Director, Director |
Insider | 78,958,928 | 6.09% | 2026-03-18 |
| Gregory George Director, 10% owner |
Insider | 33,910,962 | 2.61% | 2026-04-09 |
| Eric Allen Rose Chief Medical Officer,Director, Director |
Insider | 714,720 | 0.06% | 2026-03-18 |
| Jane Catherine Bell Director |
Insider | 622,492 | 0.05% | 2026-03-18 |
| Philip R. Krause Director |
Insider | 287,500 | 0.02% | 2026-03-18 |
| William Murray Burns Director |
Insider | 226,250 | 0.02% | 2026-03-18 |
| Philip James Facchina Director |
Insider | 123,220 | 0.01% | 2026-03-18 |
| Lynette Elizabeth Cobley Director |
Insider | 63,000 | 0.00% | 2026-03-18 |
Share count 1,296,862,776 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MESO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →